Sustained-release buprenorphine solutions
AssigneeIndivior UK Limited
InventorsMingxing Zhou, Richard L. Norton
Life of this patent
Estimating the term…
Abstract
The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.
Claims22
An injectable pharmaceutical solution comprising about 10 wt % to about 45 wt % of buprenorphine free base and a solvent mixture;
- wherein the solvent mixture comprises N-methyl-2-pyrrolidone and about 10 wt % to about 70 wt % polyethylene glycol.
An injectable pharmaceutical solution comprising about 20 wt % of buprenorphine free base and a solvent mixture;
- wherein the solvent mixture comprises N-methyl-2-pyrrolidone and polyethylene glycol in a weight ratio of about 60:40;
- and wherein the polyethylene glycol has an average molecular weight of about 300.
An injectable pharmaceutical solution comprising about 30 wt % of buprenorphine free base and a solvent mixture;
- wherein the solvent mixture comprises about 70 wt % to about 80 wt % of N-methyl-2-pyrrolidone and about 20 wt % to about 30 wt % of polyethylene glycol;
- and wherein the polyethylene glycol has an average molecular weight of about 300.
An injectable pharmaceutical solution comprising about 20 wt % of buprenorphine free base and a solvent mixture;
- wherein the solvent mixture comprises about 70 wt % to about 80 wt % of N-methyl-2-pyrrolidone and about 20 wt % to about 30 wt % of polyethylene glycol;
- and wherein the polyethylene glycol has an average molecular weight of about 300.
Dependencies are inferred from the claim text.